Revista Española de Enfermedades Digestivas · 2005 · 26 citations · 19 references
MedicinePathologyHepatologyImmunopathologyMolecular PathologyAngiogenesisBiomarkers Of Liver InjuryChronic Liver DiseaseHepatic PathologyLiver DiseaseLiver Function TestsChronic Viral HepatitisHepatitis C GenotypesHepatitis C InfectionHepatitis C Virus GenotypeProangiogenic CytokinesTie Receptor SignalingVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptors
OBJECTIVES: Our objectives were to compare angiogenesis soluble factor (ASF) levels in chronic hepatitis C (CHC) patients and healthy individuals, and to investigate potential associations between ASF levels and both histological and biochemical markers of disease progression. METHOD: Thirty-six patients (69% males) positive for HCV-RNA by PCR analysis were included in the study. All patients underwent liver biopsy before treatment. Serum levels of vascular endothelial growth factor (VEGF), soluble Flt-1 and Flk-1 receptors, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and soluble Tie-2 receptor were determined by ELISA. Fifteen healthy subjects were used as controls. RESULTS: In comparison to healthy individuals, CHC patients showed significantly increased serum levels of proangiogenic factors PlGF (22 +/- 5 vs. 18 +/- 8 pg/ml; p < 0.05), Ang-2 (1265 +/- 385 vs. 833 +/- 346 pg/ml; p < 0.005) and sFlt-1 (95 +/- 22 vs. 72 +/- 14 pg/ml; p < 0.0001). Interestingly, in CHC patients serum levels of VEGF and Tie-2 correlated with grade of inflammation, PlGF correlated with stage of fibrosis, and Flt-1 and Flk-1 correlated with serum transaminase levels (p < 0.05 in all cases). CONCLUSIONS: CHC patients showed increased serum levels of ASF, and a significant correlation was shown between serum levels of selected ASFs and grade of inflammation, stage of fibrosis, and transaminase levels.
19
Marc G. Achen, Michael Jeltsch, Eola Kukk et al. · Proceedings of the National Academy of Sciences · 1998 · 1.2K citations